Abstract:Introduction and Aims Alzheimer's disease (AD) is characterized by the abnormal accumulation of hyperphosphorylated tau proteins and amyloid-beta (A beta) peptides. Recent studies have shown that many microRNAs (miRNAs) are dysregulated in AD, and modulation of these miRNAs can influence the development of tau and A beta pathology. The brain-specific miRNA miR-128, encoded by MIR128-1 and MIR128-2, is important for brain development and dysregulated in AD. In this study, the role of miR-128 in tau and A beta pathology as well as the regulatory mechanism underlying its dysregulation were investigated.Methods The effect of miR-128 on tau phosphorylation and A beta accumulation was examined in AD cellular models through miR-128 overexpression and inhibition. The therapeutic potential of miR-128 in AD mouse model was assessed by comparing phenotypes of 5XFAD mice administered with miR-128-expressing AAVs with 5XFAD mice administered with control AAVs. Phenotypes examined included behavior, plaque load, and protein expression. The regulatory factor of miR-128 transcription was identified through luciferase reporter assay and validated by siRNA knockdown and ChIP analysis.Results Both gain-of-function and loss-of-function studies in AD cellular models reveal that miR-128 represses tau phosphorylation and A beta secretion. Subsequent investigations show that miR-128 directly inhibits the expression of tau phosphorylation kinase GSK3 beta and A beta modulators APPBP2 and mTOR. Upregulation of miR-128 in the hippocampus of 5XFAD mice ameliorates learning and memory impairments, decreases plaque deposition, and enhances autophagic flux. We further demonstrated that C/EBP alpha transactivates MIR128-1 transcription, while both C/EBP alpha and miR-128 expression are inhibited by A beta.Conclusion Our findings suggest that miR-128 suppresses AD pathogenesis, and could be a promising therapeutic target for AD. We also find a possible mechanism underlying the dysregulation of miR-128 in AD, in which A beta reduces miR-128 expression by inhibiting C/EBP alpha.

MicroRNA-425-5p promotes tau phosphorylation and cell apoptosis in Alzheimer’s disease by targeting heat shock protein B8

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

MicroRNA-139 Modulates Alzheimer's-associated Pathogenesis in SAMP8 Mice by Targeting Cannabinoid Receptor Type 2.

microRNA‐425 loss mediates amyloid plaque microenvironment heterogeneity and promotes neurodegenerative pathologies

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

MiR-124-3p Attenuates Hyperphosphorylation of Tau Protein-Induced Apoptosis Via Caveolin-1-pi3k/akt/gsk3β Pathway in N2a/APP695swe Cells

Loss of miR-369 Promotes Tau Phosphorylation by Targeting the Fyn and Serine/Threonine-Protein Kinase 2 Signaling Pathways in Alzheimer’s Disease Mice

miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression

MiR-191-5p alleviates microglial cell injury by targeting Map3k12 (mitogen-activated protein kinase kinase kinase 12) to inhibit the MAPK (mitogen-activated protein kinase) signaling pathway in Alzheimer’s disease

LncRNA RP11-59J16.2 aggravates apoptosis and increases tau phosphorylation by targeting MCM2 in AD

MicroRNA‐128 Suppresses Tau Phosphorylation and Reduces Amyloid‐beta Accumulation by Inhibiting the Expression of GSK3β, APPBP2, and Mtor in Alzheimer's Disease

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Bioinformatics analysis indicates that microRNA‐628‐5p overexpression may alleviate Alzheimer's disease by targeting TYROBP

The Role of MicroRNAs in Aβ Deposition and Tau Phosphorylation in Alzheimer’s Disease

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy

MicroRNAs: Pioneering Regulators in Alzheimer’s Disease Pathogenesis, Diagnosis, and Therapy

miR-429-3p mediates memory decline by targeting MKP-1 to reduce surface GluA1-containing AMPA receptors in a mouse model of Alzheimer's disease

miRNA375-3p/rapamycin mediates the mTOR pathway by decreasing PS1, enhances microglial cell activity to regulate autophagy in Alzheimer's disease

Downregulation of miR-181c-5p in Alzheimer's disease weakens the response of microglia to Aβ phagocytosis

miR-200a-3p promotes b-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer's disease

MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice.